Liraglutide administration in NASH subjects resulted in raised insulin sensitivity, decrease of DNL, reduced BMI, cholesterol-LDL, and suppression of lipolysis especially within the subcutaneous adipose tissue [172, 173]. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.